Research ArticleCancer

A Mucin 16 bispecific T cell–engaging antibody for the treatment of ovarian cancer

See allHide authors and affiliations

Science Translational Medicine  19 Jun 2019:
Vol. 11, Issue 497, eaau7534
DOI: 10.1126/scitranslmed.aau7534

You are currently viewing the editor's summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Opening up options in ovarian cancer

The glycoprotein Mucin 16 (MUC16) has been previously investigated as a targetable tumor antigen. Crawford et al. now report on a bispecific antibody that binds CD3 and MUC16, which could potentially be used in ovarian cancer treatment. The antibody induced T cell activation and ovarian cancer cells killing both in vitro and in mouse models. This antibody worked well with checkpoint blockade and was shown to be safe when administered to nonhuman primates. A clinical trial using this antibody is already underway.

View Full Text